AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 221 min read$ERIC

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures were mixed on Tuesday. Ericsson (NASDAQ:ERIC) fell 4.3% to $9.81 after a Morgan Stanley analyst downgraded it and cut the price target. Other stocks moving lower include Quest Diagnostics (NYSE:DGX), Rambus (NASDAQ:RMBS), and Lexeo Therapeutics (NASDAQ:LXEO).

Original reporting
benzinga.com
Published Sep 22, 2026, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$ERIC
Bearish
high confidence
Mentioned
$ERIC · $LXEO
Relevance
6/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$ERICBearishMed
01

Why it matters

Downgrade of Ericsson and acquisition announcement by Lexeo are the primary new facts driving the price moves.

02

Market read

Fresh analyst downgrade and acquisition news create immediate trading opportunities in the affected stocks.

03

What to watch

Potential long‑term upside from Ericsson's 5G rollout and Lexeo's pipeline progress.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

The article lists several US stocks that fell in pre‑market trading, highlighting analyst actions and corporate deals as catalysts.

Company-level read

Ticker impact

$ERICBearishHigh confidence
Context

Morgan Stanley downgraded Ericsson to Underweight and cut the price target to $9, causing a 4.3% pre‑market drop.

Expected impact

Further downside pressure in early trading.

Evidence & confidence

Downgrade is a fresh catalyst; price already fell 4.3% pre‑market.

$LXEOBearishMedium confidence
Context

Lexeo Therapeutics announced a deal to acquire Mantle Therapeutics and new collaborations in Friedreich Ataxia, sending the stock down 5.4% pre‑market.

Expected impact

Potential rebound if deal terms are viewed positively, but immediate sell pressure expected.

Evidence & confidence

Deal news is new but market reaction is a modest decline.

Market effects

Sector

Telecom equipment sector may see broader pressure as analyst sentiment tightens.

Regional

European tech stocks could face slight pullback in early US trading.

Global

Limited to US‑listed telecom and biotech names.

Counterpoint

What could challenge this read

If the downgrade is overly aggressive, the stock could rebound on short‑covering.

Key entities

  • Analyst Firm
    Morgan Stanley

    Issued downgrade and price target cut for Ericsson.

  • Target Company
    Mantle Therapeutics

    To be acquired by Lexeo Therapeutics.

Read at source← All news

Related articles

SEP 22
$LXEOMed

Why is Lexeo Therapeutics stock gaining today?

Lexeo Therapeutics (LXEO) stock rose 4.2% pre-market after announcing strategic transactions, including the acquisition of Mantle Therapeutics for up to $21.3M. The deal adds four FA programs to its pipeline, with LX3010 showing early positive data. Lexeo also entered three research collaborations and maintained its cash runway guidance. Raymond James reiterated a Strong Buy rating and $24.00 price target.

investing.com2 min
SEP 22
$LXEOHighAI 8/10

Lexeo stock rises on $21.3M Mantle deal for FA therapies

Lexeo Therapeutics (NASDAQ:LXEO) shares rose 5.4% premarket after announcing a deal to acquire Mantle Therapeutics for up to $21.3M, expanding its Friedreich ataxia treatment platform. The acquisition includes four therapeutic programs, with $8.3M upfront payment and $13M in potential milestones. Lexeo also launched three research collaborations and expects to submit an IND in 2027. Raymond James reiterated a Strong Buy rating and $24.00 price target.

investing.com1 min
SEP 22
$ERICMed

Why is LM Ericsson stock down today?

LM Ericsson (ERIC) stock fell 3.7% to SEK 96.62 after Morgan Stanley downgraded it to Underweight, citing declining North American revenues and falling margins. The bank lowered its price targets and warned of potential earnings revisions due to headwinds in the mobile Radio Access Network equipment business. Ericsson's Q3 guidance also indicates a margin decline. Morgan Stanley prefers rival Nokia for its AI infrastructure exposure.

investing.com2 min
SEP 22
$ERICMed

Ericsson dips as Morgan Stanley downgrades stock on falling NA revenue, margins

Morgan Stanley downgraded Ericsson (ERIC) to Underweight, lowering its price target to 90 SEK and $9 for ADRs, citing declining North American revenues and falling margins. Shares dropped over 3% in Stockholm. The bank expects flat mobile RAN market growth and margin declines through 2028, reducing 2027 EBIT and EPS estimates by 5% and 6%, respectively. Ericsson's stock trades at 16x earnings, above its 5-year average.

investing.com2 min
SEP 22
$ERICMed

Morgan Stanley downgrades Ericsson stock rating on margin pressure

Morgan Stanley downgraded Ericsson (NASDAQ:ERIC) to Underweight, lowering its price target to $9.00. The firm expects flat mobile RAN market growth and margin pressure due to rising input costs. Ericsson's Q2 revenues declined 5% YoY in North America, with Q3 guidance showing a 100 bps margin decline. Morgan Stanley reduced 2027 EBIT and EPS estimates by 5% and 6%, respectively. Ericsson's P/E is 11.19, with a PEG ratio of 0.32, suggesting potential undervaluation.

investing.com2 min